However, Diez et al. in addition to FA-patient-derived cell lines and healthy CD34+ cells also used FA CD34+ cells to demonstrate the feasibility of correcting the FA phenotype by ZFN-mediated introduction of an FANCA donor into the AAVS1 ‘safe harbor’ locus [174]. The gene discussed is FANCA; the disease is Friedreich ataxia.